Antifungal News and Research

RSS

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

Deinobiotics project receives €1.35 million for developing novel antibiotic, antifungal compounds

Deinove, the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that its Deinobiotics project is to receive a total of €1.35 million in grants and loans.

15 Nov 2010

PolyMedix announces publication of defensin-mimetic compounds in Molecular Oral Microbiology

PolyMedix, Inc. an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced that data from two separate pre-clinical research studies were published in the December issue of Molecular Oral Microbiology.

10 Nov 2010

PinPointe FootLaser receives FDA clearance for treatment of nail fungus

The podiatry practice of Mark E. Spier, DPM, announced today that the PinPointe™ FootLaser™ has received clearance from the U.S. Food and Drug Administration (FDA) for the treatment of nail fungus (onychomycosis). Dr. Spier is the first certified provider of the treatment in the Baltimore area.

26 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Maven Semantic updates Antiviral research database

Maven Semantic announces updates to their Antiviral research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

25 Oct 2010

Research calls for better environmental risk assessments of pharmaceuticals

The strategies used to assess the environmental risks posed by pharmaceuticals are not enough to protect natural microbial communities, reveals a researcher from the University of Gothenburg (Sweden) who is calling for better environmental risk assessments.

19 Oct 2010

NovaBay to present two poster presentations at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA).

15 Oct 2010

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Quick-Med Technologies, Inc.a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today its NIMBUS and Stay Fresh antimicrobial technologies will be highlighted at the 2010 Clinical Symposium on Advances in Skin and Wound Care, to be held in Orlando, Florida from September 30 – October 3, 2010.

29 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Ants use antibiotics to inhibit growth of unwanted fungi, bacteria

Research led by Dr Matt Hutchings and published today in the journal BMC Biology shows that ants use the antibiotics to inhibit the growth of unwanted fungi and bacteria in their fungus cultures which they use to feed their larvae and queen.

27 Aug 2010

Montana State University offers new biomedical technologies for prevention, treatment of viral infections

Researchers at Montana State University have developed six new biomedical technologies that could have applications for treating antibiotic resistant infections, fungal infections and viral infections; boosting humans' innate immunity and improving scientists' ability to study such compounds. The technologies are available for licensing to interested companies and entrepreneurs.

19 Aug 2010

Dermatologist discusses on common nail ailment prevention

For many people, the phrase "tough as nails" doesn't apply to their own nails. Instead of strong nails, their nails may be brittle and break or split easily. Or, nail fungus might cause nails to look unattractive and unhealthy. Fortunately, dermatologists can help people improve the health and overall appearance of their nails with proper diagnosis and treatment.

6 Aug 2010

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

6 Aug 2010

AdvanDx's 90 minutes protocol for Yeast Traffic Light PNA FISH test receives FDA 510(k) clearance

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its Yeast Traffic Light® PNA FISH® test. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

30 Jul 2010

Safeguard Scientifics second-quarter aggregate revenue of partner companies increase 47% to $91.6 million

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009.

29 Jul 2010

Johns Hopkins scientist wins $2.5M NIH Director's Pioneer Award

A Johns Hopkins scientist who proposes to design and create an all-new series of novel drugs is one of 17 winners of a special grant known as a Director's Pioneer Award from the National Institutes of Health.

27 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010